IL257442B2 - Process for preparing parp inhibitor, crystalline forms and their uses - Google Patents

Process for preparing parp inhibitor, crystalline forms and their uses

Info

Publication number
IL257442B2
IL257442B2 IL257442A IL25744218A IL257442B2 IL 257442 B2 IL257442 B2 IL 257442B2 IL 257442 A IL257442 A IL 257442A IL 25744218 A IL25744218 A IL 25744218A IL 257442 B2 IL257442 B2 IL 257442B2
Authority
IL
Israel
Prior art keywords
compound
crystalline form
hydrate
cancer
solvent
Prior art date
Application number
IL257442A
Other languages
English (en)
Hebrew (he)
Other versions
IL257442A (en
IL257442B (en
Original Assignee
Beigene Ltd
Beigene Switzerland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58099633&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL257442(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beigene Ltd, Beigene Switzerland Gmbh filed Critical Beigene Ltd
Publication of IL257442A publication Critical patent/IL257442A/en
Publication of IL257442B publication Critical patent/IL257442B/en
Publication of IL257442B2 publication Critical patent/IL257442B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
IL257442A 2015-08-25 2016-08-22 Process for preparing parp inhibitor, crystalline forms and their uses IL257442B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2015088003 2015-08-25
PCT/CN2016/096200 WO2017032289A1 (en) 2015-08-25 2016-08-22 Process for preparing parp inhibitor, crystalline forms, and uses thereof

Publications (3)

Publication Number Publication Date
IL257442A IL257442A (en) 2018-04-30
IL257442B IL257442B (en) 2022-11-01
IL257442B2 true IL257442B2 (en) 2023-03-01

Family

ID=58099633

Family Applications (2)

Application Number Title Priority Date Filing Date
IL257442A IL257442B2 (en) 2015-08-25 2016-08-22 Process for preparing parp inhibitor, crystalline forms and their uses
IL296835A IL296835A (en) 2015-08-25 2016-08-22 Process for preparing parp inhibitor, crystalline forms, and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL296835A IL296835A (en) 2015-08-25 2016-08-22 Process for preparing parp inhibitor, crystalline forms, and uses thereof

Country Status (15)

Country Link
US (1) US10457680B2 (cg-RX-API-DMAC7.html)
EP (1) EP3341375B1 (cg-RX-API-DMAC7.html)
JP (1) JP6940039B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180041748A (cg-RX-API-DMAC7.html)
CN (2) CN107922425B (cg-RX-API-DMAC7.html)
AU (1) AU2016312011B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018003634B1 (cg-RX-API-DMAC7.html)
CA (1) CA2994895A1 (cg-RX-API-DMAC7.html)
EA (1) EA037366B1 (cg-RX-API-DMAC7.html)
IL (2) IL257442B2 (cg-RX-API-DMAC7.html)
MX (1) MX385450B (cg-RX-API-DMAC7.html)
NZ (1) NZ739876A (cg-RX-API-DMAC7.html)
TW (1) TWI736550B (cg-RX-API-DMAC7.html)
WO (1) WO2017032289A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201800765B (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2797921T3 (cg-RX-API-DMAC7.html) 2011-12-31 2018-02-03
EA037366B1 (ru) 2015-08-25 2021-03-18 Бейджин, Лтд. Способ получения ингибитора parp, кристаллические формы и их применения
US11202782B2 (en) 2016-09-27 2021-12-21 Beigene, Ltd. Treatment cancers using a combination comprising PARP inhibitors
CN110392687B (zh) * 2017-02-28 2022-08-02 百济神州(苏州)生物科技有限公司 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式及其用途
US12121518B2 (en) 2017-03-09 2024-10-22 The Board Of Supervisors Of Louisiana State Universi And Agricultural And Mechanical College PARP-1 and methods of use thereof
WO2018165615A1 (en) 2017-03-09 2018-09-13 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Parp-1 and methods of use thereof
EP3654985A4 (en) * 2017-07-17 2021-04-07 BeiGene, Ltd. TREATMENT OF CANCERS USING A COMBINATION INCLUDING PARP INHIBITORS, TEMOZOLOMIDE AND / OR RADIATION THERAPY
CA3097312A1 (en) * 2018-05-18 2019-11-21 Novartis Ag Crystalline forms of a tlr7/tlr8 inhibitor
TW202002985A (zh) * 2018-06-01 2020-01-16 英屬開曼群島商百濟神州有限公司 在胃癌治療中的parp抑制劑維持療法
USD926356S1 (en) * 2019-03-14 2021-07-27 Tuanfang Liu Battery for electronic cigarette
CN113004279B (zh) * 2019-05-10 2023-01-06 百济神州(苏州)生物科技有限公司 一种控制含parp抑制剂倍半水合物产物的含水量的方法
CN111171001B (zh) * 2019-05-16 2022-04-29 百济神州(苏州)生物科技有限公司 一种parp抑制剂中间体的结晶方法
CN111171002B (zh) * 2019-05-16 2021-04-06 百济神州(苏州)生物科技有限公司 一种parp抑制剂中间体的制备方法
MX2021014339A (es) * 2019-05-31 2022-01-06 Beigene Ltd Preparacion de granulo inhibidor de parp y proceso de preparacion del mismo.
CN112007011B (zh) * 2019-05-31 2024-07-23 百济神州(苏州)生物科技有限公司 一种parp抑制剂微丸胶囊及其制备工艺
WO2021046014A1 (en) 2019-09-03 2021-03-11 Teva Czech Industries S.R.O Solid state forms of pamiparib and process for preparation thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013097225A1 (en) * 2011-12-31 2013-07-04 Beigene, Ltd. Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20691B (sl) 1999-01-11 2008-10-31 Agouron Pharma Triciklični inhibitorji poli(ADP-riboza) polimeraz
ATE478664T1 (de) * 2000-12-01 2010-09-15 Eisai Inc Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
HRP20050624A2 (en) * 2003-01-09 2006-02-28 Pfizer Inc. Diazepinoindole derivatives as kinaze inhibitors
LT2767537T (lt) 2008-08-06 2017-08-10 Medivation Technologies, Inc. Poli(adp-ribozės)polimerazės (parp) dihidropiridoftalazinono inhibitoriai
HUE060420T2 (hu) 2013-09-13 2023-02-28 Beigene Switzerland Gmbh Anti-PD1 antitestek, valamint terapeutikumként és diagnosztikumként történõ alkalmazásuk
KR102003754B1 (ko) 2014-07-03 2019-07-25 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
US9637488B2 (en) 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
EA037366B1 (ru) 2015-08-25 2021-03-18 Бейджин, Лтд. Способ получения ингибитора parp, кристаллические формы и их применения
US11202782B2 (en) * 2016-09-27 2021-12-21 Beigene, Ltd. Treatment cancers using a combination comprising PARP inhibitors
CN110392687B (zh) * 2017-02-28 2022-08-02 百济神州(苏州)生物科技有限公司 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式及其用途
EP3654985A4 (en) * 2017-07-17 2021-04-07 BeiGene, Ltd. TREATMENT OF CANCERS USING A COMBINATION INCLUDING PARP INHIBITORS, TEMOZOLOMIDE AND / OR RADIATION THERAPY
CN113004279B (zh) * 2019-05-10 2023-01-06 百济神州(苏州)生物科技有限公司 一种控制含parp抑制剂倍半水合物产物的含水量的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013097225A1 (en) * 2011-12-31 2013-07-04 Beigene, Ltd. Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAIRA M R ED - MONTCHAMP JEAN-LUC,, CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS, 31 December 1998 (1998-12-31) *

Also Published As

Publication number Publication date
WO2017032289A1 (en) 2017-03-02
JP6940039B2 (ja) 2021-09-22
IL257442A (en) 2018-04-30
EP3341375B1 (en) 2022-04-13
BR112018003634B1 (pt) 2023-11-21
CA2994895A1 (en) 2017-03-02
CN107922425A (zh) 2018-04-17
US20190177325A1 (en) 2019-06-13
KR20180041748A (ko) 2018-04-24
TW201718586A (zh) 2017-06-01
BR112018003634A8 (pt) 2023-01-17
AU2016312011A1 (en) 2018-03-08
US10457680B2 (en) 2019-10-29
MX2018002322A (es) 2018-04-11
CN112521390A (zh) 2021-03-19
MX385450B (es) 2025-03-18
ZA201800765B (en) 2019-10-30
BR112018003634A2 (en) 2018-11-21
JP2018528199A (ja) 2018-09-27
EA037366B1 (ru) 2021-03-18
AU2016312011B2 (en) 2021-02-04
CN107922425B (zh) 2021-06-01
EP3341375A4 (en) 2019-01-16
EP3341375A1 (en) 2018-07-04
IL296835A (en) 2022-11-01
IL257442B (en) 2022-11-01
EA201890547A1 (ru) 2018-07-31
NZ739876A (en) 2022-09-30
TWI736550B (zh) 2021-08-21

Similar Documents

Publication Publication Date Title
IL257442B2 (en) Process for preparing parp inhibitor, crystalline forms and their uses
TW202128691A (zh) Ｋｒａｓ 突變蛋白抑制劑
CN113874019A (zh) 用于治疗nash/nafld及相关疾病的包含作为glp-1r激动剂的苯并二氧杂环戊烯的组合
JP6197125B2 (ja) 化合物の組成物およびその使用
CA3119526A1 (en) Small molecule degraders of helios and methods of use
NZ735715A (en) Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
US9809568B2 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
CN113788824A (zh) 吡啶化合物
TW201625620A (zh) 作為蛋白去乙醯酶抑制劑及雙蛋白去乙醯酶蛋白激酶抑制劑之雜環氧肟酸及其使用方法
TWI823420B (zh) 用作cdk激酶抑制劑的化合物及其應用
CN115433187A (zh) 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式组合物及其用途
TW201643143A (zh) 抑制氧化壓迫引發的神經細胞死亡之化合物
CN105218548A (zh) 一种新型杂环化合物及其制备方法和作为激酶抑制剂的用途
AU2020270908B2 (en) Degradation of AKT by conjugation of ATP-competitive AKT inhibitor GDC-0068 with E3 ligase ligands and methods of use
WO2021143922A1 (zh) 一种溴区结构域蛋白抑制剂的晶型、盐型及其制备方法
WO2016171142A1 (ja) 複素環化合物
CN119173510A (zh) 一种羟基酰胺类衍生物及其应用
HK40040143A (en) Process for preparing parp inhibitor, crystalline forms, and uses thereof
TW202519531A (zh) 含丙烯酮類生物抑制劑的晶型及其製備方法和應用
JP2020521818A (ja) プロテインキナーゼ阻害剤として有用なカルボン酸誘導体
CN114426541A (zh) 氮杂芳基化合物及其用途
HK40063773A (en) Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases